Aurobindo Pharma logo

AUROPHARMA - Aurobindo Pharma Share Price

₹943.7 36.3  4.0%

Last Trade - 09/04/21

Large Cap
Market Cap £5.40bn
Enterprise Value £5.56bn
Revenue £2.43bn
Position in Universe 78th / 3106
Unlock AUROPHARMA Revenue
Relative Strength (%)
1m +12.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.81%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
121,205 139,552 150,899 164,998 195,636 230,985 251,391 264,972 +13.8%
+34.9 +27.7 +13.5 +5.5 +0.5 +17.6 +25.8 -2.29
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020,Aurobindo Pharma Ltd revenues increased 11% to RS187.73B.Net income increased from RS19.81B to RS45.33B. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Net incomebenefited from Gain on Acquisition decrease from RS383.8M(expense) to RS1.52B (income), Others increase fromRS536.1M to RS2.13B (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AUROPHARMA
Graphical History



Net Income


Normalised EPS


PE Ratio Range


Dividend Yield Range

AUROPHARMA Dividend Yield Range Unlock AUROPHARMA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
Profile Summary

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated December 26, 1986
Public Since January 19, 1995
No. of Shareholders: 212,246
No. of Employees: 18,469
Sector Healthcare
Industry Pharmaceuticals
Index S&P BSE 100 ,
Exchange National Stock Exchange of India
Shares in Issue 585,938,609
Free Float (0.0%)
Eligible for
AUROPHARMA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AUROPHARMA
Upcoming Events for AUROPHARMA
Monday 24th May, 2021 Estimate
Full Year 2021 Aurobindo Pharma Ltd Earnings Release
Tuesday 10th August, 2021 Estimate
Q1 2022 Aurobindo Pharma Ltd Earnings Release
Frequently Asked Questions for Aurobindo Pharma
What is the Aurobindo Pharma share price?

As of 09/04/21, shares in Aurobindo Pharma are trading at ₹943.7, giving the company a market capitalisation of £5.40bn. This share price information is delayed by 15 minutes.

How has the Aurobindo Pharma share price performed this year?

Shares in Aurobindo Pharma are currently trading at ₹943.7 and the price has moved by 0.105k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aurobindo Pharma price has moved by 25.33% over the past year.

What are the analyst and broker recommendations for Aurobindo Pharma?

Of the analysts with advisory recommendations for Aurobindo Pharma, there are there are currently 16 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aurobindo Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aurobindo Pharma next release its financial results?

Aurobindo Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Aurobindo Pharma dividend yield?

The Aurobindo Pharma dividend yield is 0.61% based on the trailing twelve month period.

Does Aurobindo Pharma pay a dividend?

Last year, Aurobindo Pharma paid a total dividend of 5.75, and it currently has a trailing dividend yield of 0.61%. Looking ahead, Aurobindo Pharma has not announced an ex-dividend date yet.

When does Aurobindo Pharma next pay dividends?

Aurobindo Pharma has yet to annouce their ex-dividend date. The historic dividend yield on Aurobindo Pharma shares is currently 0.61%.

How do I buy Aurobindo Pharma shares?

To buy shares in Aurobindo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aurobindo Pharma?

Shares in Aurobindo Pharma are currently trading at ₹943.7, giving the company a market capitalisation of £5.40bn.

Where are Aurobindo Pharma shares listed? Where are Aurobindo Pharma shares listed?

Here are the trading details for Aurobindo Pharma:

Country of listing: India
Exchange: NSI
Ticker Symbol: AUROPHARMA
What kind of share is Aurobindo Pharma?

Based on an overall assessment of its quality, value and momentum, Aurobindo Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aurobindo Pharma share price forecast 2021?

Shares in Aurobindo Pharma are currently priced at ₹943.7. At that level they are trading at 13.38% discount to the analyst consensus target price of 0.00.

Analysts covering Aurobindo Pharma currently have a consensus Earnings Per Share (EPS) forecast of 61.823 for the next financial year.

How can I tell whether the Aurobindo Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurobindo Pharma. Over the past six months, the relative strength of its shares against the market has been -10.23%. At the current price of ₹943.7, shares in Aurobindo Pharma are trading at 10.15% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aurobindo Pharma PE Ratio?

The Aurobindo Pharma PE ratio based on its reported earnings over the past 12 months is 16.94. The shares are currently trading at ₹943.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Aurobindo Pharma?

Aurobindo Pharma's management team is headed by:

P.V. Reddy - NED
K. Nityananda Reddy - VCH
M. Sivakumaran - EDR
B. Adi Reddy - CCO
M. Madan Reddy - EDR
P. Sarath Reddy - EDR
K Ragunathan - NEC
N. Govindarajan - MDR
Santhanam Subramanian - CFO
Avnit Singh - NID
Savita Mahajan - NID
Girish Vanvari - NID
Who are the major shareholders of Aurobindo Pharma?

Here are the top five shareholders of Aurobindo Pharma based on the size of their shareholding:

RPR Sons Advisors Pvt. Ltd. Corporation
Percentage owned: 6.75% (39.6m shares)
HDFC Asset Management Co., Ltd. Investment Advisor
Percentage owned: 5.3% (31.1m shares)
Reddy (Nityananda K) Individual Investor
Percentage owned: 4.33% (25.4m shares)
Kambam (Kirthi Reddy) Individual Investor
Percentage owned: 3.49% (20.5m shares)
Reddy (Ramaprasad P V) Individual Investor
Percentage owned: 3.07% (18.0m shares)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.